



AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A phosphatidyl-L-serine sodium salt productcomposition having a fatty acid composition identical to that of soybean lecithin and a degree of peroxidation of less than 5 produced by reacting α -phosphatides of formula (II):




wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with serine a primary or secondary alcohol with a chain length of between C2 to C4, optionally substituted with one or more polar groups selected from the group consisting of amino, hydroxy and carboxy, in a single aqueous phase in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction, and wherein said phosphatides of formula II are obtained from soybean, wherein said phospholipase D is purified by eluting on an anionic cationic exchange resin at a pH of 6.2.

2. **(Currently Amended)** The A phosphatidyl-L-serine sodium salt productcomposition having a fatty acid composition identical to that of egg lecithin and a degree of peroxidation of less than 5 produced by reacting α -phosphatides of formula (II):




wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with serine a primary or secondary alcohol with a chain length of between C2 to C4, optionally substituted with one or more polar groups selected from the group consisting of amino, hydroxy and carboxy, in a single aqueous phase in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction, and wherein said phosphatides of formula II are obtained from egg, wherein said phospholipase D is purified by eluting on an anionic cationic exchange resin at a pH of 6.2.

3. (Currently Amended) A phosphatidyl-L-serine sodium salt productcomposition having a fatty acid composition identical to that of soybean lecithin and a degree of peroxidation of less than 5 produced by reacting α -phosphatides of formula (II):



wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with serine a primary or secondary alcohol with a chain length of between C2 to C4, optionally substituted with one or more polar groups selected from the group consisting of amino, hydroxy and carboxy, in a single aqueous phase in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction, and wherein said phosphatides of formula II are obtained from soybean and wherein said phospholipase D is purified by eluting on an anionic cationic exchange resin at a pH of 6.2.

4. (Currently Amended) A phosphatidyl-L-serine sodium salt productcomposition having a fatty acid composition identical to that of egg lecithin and a degree of peroxidation of less than 5 produced by reacting α -phosphatides of formula (II):




wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with serine a primary or secondary alcohol with a chain length of between C2 to C4, optionally substituted with one or more polar groups selected from the group consisting of amino, hydroxy and carboxy, in a single aqueous phase in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction and wherein said phosphatides of formula II are obtained from soybean and wherein said phospholipase D is purified by eluting on an anionic cationic exchange resin at a pH of 6.2.

5. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a phosphatide-phosphatidyl-L-serine sodium salt of formula (I)




wherein R is diacylglycerol and R₁ is an hydroxyl group,

made by the process of reacting a phosphatide of formula (II):




wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with serine a primary or secondary alcohol with a chain length of between C2 to C4, optionally substituted with one or more polar groups selected from the group consisting of amino, hydroxy and carboxy, in a single aqueous phase in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction to obtain said phosphatide according to formula (I).

6. (Currently Amended) A cosmetic composition comprising a pharmaceutically acceptable carrier and a phosphatide-phosphatidyl-L-serine sodium salt of formula (I)



wherein R is diacylglycerol and R₁ is an hydroxyl group,


made by the process of reacting a phosphatide of formula (II):



wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with serine a primary or secondary alcohol with a chain length of between C2 to C4, optionally substituted with


one or more polar groups selected from the group consisting of amino, hydroxy and carboxy, in a single aqueous phase in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction to obtain said phosphatide according to formula (I).

7. **(Currently Amended)** A food and dietary supplement comprising a carrier and a phosphatidyl-L-serine sodium salt phosphatide of formula (I)



wherein R is diacylglycerol and R₁ is an hydroxyl group,

made by the process of reacting a phosphatide of formula (II):



wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with serine a primary or secondary alcohol with a chain length of between C2 to C4, optionally substituted with one or more polar groups selected from the group consisting of amino, hydroxy and carboxy, in a single aqueous phase in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction to obtain said phosphatide according to formula (I).

8. **(Currently Amended)** The food and dietary supplement according to claim 7, wherein the phosphatide according to formula (I) is phosphatidyl-L-serine and wherein the *Streptomyces hachijoense* strain used to catalyze the reaction is ATCC 19769.

9. **(Currently Amended)** A pharmaceutical composition capable of being administered orally comprising a pharmaceutically acceptable carrier and the phosphatidyl-L-serine productcomposition according to claim 3 or 4.

10. **(Currently Amended)** A cosmetic composition for topical application to the skin comprising a pharmaceutically acceptable carrier and phosphatidyl-L-serine ~~made by the process~~ according to claim 3 or 4.

11. **(Currently Amended)** A food and dietary supplement capable of being administered orally comprising a carrier and phosphatidyl-L-serine ~~made by the process~~ according to claim 3 or 4.

12. **(Original)** A method of treating psycho-physical stress, attention, concentration and memory deficits commonly associated with advancing age, comprising administering a therapeutically effective amount of a pharmaceutical composition according to claim 5.

13. **(Original)** A method of treating dermatitis or skin with impaired physiological functions comprising applying a cosmetic composition according to claim 6 to the skin.

14. **(Original)** A method of treating psycho-physical stress, attention, concentration and memory deficits commonly associated with advancing age comprising administering a food and dietary supplement according to claim 7.

15. **(Currently Amended)** The pharmaceutical composition according to claim 5 or 9 in the form of a capsule, tablet or granule.

16. **(Currently Amended)** The cosmetic composition according to claim 6 or 10 in the form of a cream or a gel.

17. **(Original)** A food and dietary supplement according to claim 7 in the form of a capsule, tablet or granule.

18. **(Original)** A food and dietary supplement according to claim 11 in the form of a capsule, tablet or granule.

19. **(Original)** The food and dietary supplement according to claim 8, wherein the phosphatide of formula (II) is selected from the group consisting of purified soybean lecithin and crude soybean lecithin.

20. **(Currently Amended)** The phosphatidyl-L-serine productcomposition according to claim 1 or 2, wherein the phosphatidyl-L-serine productcomposition is at least 95% pure.

21. **(Currently Amended)** The phosphatidyl-L-serine productcomposition according to claim 1 or 2, wherein the formula II phosphatide reactant is phosphatidylcholine, and wherein said phosphatidylcholine reactant is completely converted to product.